Every material Form 8-K Guardant Health, Inc. has filed with the SEC since November 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Guardant Health reported third quarter 2026 revenue of $361.0 million, up 36% from a year earlier, and raised its full-year 2026 revenue guidance to $1.36 to $1.37 billion. The GAAP net loss widened to $124.4 million, and the company also raised its expected full-year free cash flow burn, so shareholders see stronger sales alongside higher losses and cash use.
Q3 2026 revenue of $361.0 million, up 36%; Screening revenue rose 180% to $67.6 million on 83,000 Shield tests
GAAP net loss of $124.4 million, or $0.93 per share, versus $92.7 million, or $0.74 per share, a year earlier; non-GAAP net loss narrowed to $38.8 million from $48.3 million
2026 revenue guidance raised to $1.36 to $1.37 billion from $1.34 to $1.36 billion; full-year free cash flow burn now expected at $205 million to $220 million, up from $195 million to $205 million
Guardant Health increased its board to 11 seats and appointed Kevin R. Sayer, former Dexcom CEO, as a Class II director effective November 2, 2026. The company also named Robert A. Parks as Chief Accounting Officer and principal accounting officer on the same date, replacing no named predecessor in the filing. The changes add board and finance leadership but the filing discloses no financial results.
Kevin R. Sayer, 68, appointed Class II director effective November 2, 2026, with a term expiring at the 2029 Annual Meeting
Sayer to receive a restricted stock unit award valued at $500,000 and a $60,000 annual cash retainer
Robert A. Parks, 54, appointed Chief Accounting Officer and principal accounting officer; previously CAO of Fortrea Holdings Inc. from August 2024 to August 2026
Guardant Health's board approved performance-based restricted stock unit awards to co-CEOs Helmy Eltoukhy and AmirAli Talasaz, each with a target of 465,413 PSUs. The awards pay out only if the company's total shareholder return beats a set percentile versus S&P 500 constituents over three-year and five-year periods, so the grants create no value unless relative returns meet those thresholds.
Each co-CEO received a grant of 465,413 PSUs at target, approved November 2, 2026.
25% of target PSUs cover a three-year period (June 1, 2026 to May 31, 2029); 75% cover a five-year period (June 1, 2026 to May 31, 2031).
Payout ranges from 0% of target below the 40th percentile to 250% at or above the 90th percentile; total vesting is capped at 250% of target.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Guardant Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →